BCM
ALLO icon

Bridgeway Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Bridgeway Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$520K Hold
250,000
– – 0.01% 841
2026
Q1 		$610K Hold
250,000
– – 0.01% 789
2025
Q4 		$343K Hold
250,000
– – 0.01% 897
2025
Q3 		$310K Buy
+250,000
New +$298K 0.01% 917

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bridgeway Capital Management's ALLO Position: Q2 2026 in Review

Bridgeway Capital Management held its Allogene Therapeutics (ALLO) position steady in Q2 2026 at 250,000 shares worth $520K. The position accounts for 0.01% of the portfolio, ranked #841.

Bridgeway Capital Management first reported a position in ALLO in Q3 2025 and has held it in 4 quarters since. The position peaked at $610K in Q1 2026. 210 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Bridgeway Capital Management held 250,000 shares of Allogene Therapeutics worth $520K as of Q2 2026.
  • Bridgeway Capital Management left its Allogene Therapeutics share count unchanged in Q2 2026.
  • Allogene Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #841 holding.
  • Bridgeway Capital Management first reported a position in Allogene Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Bridgeway Capital Management's Allogene Therapeutics position peaked at $610K in Q1 2026.
  • 210 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.